|
1
|
Foucault C, Mordant P, Grand B, et al:
Unexpected extensions of non-small-cell lung cancer diagnosed
during surgery: revisiting exploratory thoracotomies and incomplete
resections. Interact Cardiovasc Thorac Surg. 16:667–672. 2013.
|
|
2
|
Wheelock EF and Dingle JH: Observations on
the repeated administration of viruses to a patient with acute
leukamia. A preliminary report. N Engl J Med. 271:645–651.
1964.
|
|
3
|
Cassel WA and Garrett RE: Newcastle
disease virus as an antineoplastic agent. Cancer. 18:863–868.
1965.
|
|
4
|
Reichard KW, Lorence RM and Cascino CJ:
Selective replication of Newcastle disease virus (NDV) in cancer
cells is associated with virus-induced cell fusion. Proc Am Assoc
Cancer Res. 33:5211992.
|
|
5
|
Bukreyev A, Huang Z, Yang L, et al:
Recombinant Newcastle disease virus expressing a foreign viral
antigen is attenuated and highly immunogenic in primates. J Virol.
79:13275–13284. 2005.
|
|
6
|
DiNapoli JM, Kotelkin A, Yang L, et al:
Newcastle disease virus, a host range-restricted virus, as a
vaccine vector for intranasal immunization against emerging
pathogens. Proc Natl Acad Sci USA. 104:9788–9793. 2007.
|
|
7
|
DiNapoli JM, Nayak B, Yang L, et al:
Newcastle disease virus-vectored vaccines expressing the
hemagglutinin or neuraminidase protein of H5N1 highly pathogenic
avian influenza virus protect against virus challenge in monkeys. J
Virol. 84:1489–1503. 2010.
|
|
8
|
Martinez-Sobrido L, Gitiban N,
Fernandez-Sesma A, et al: Protection against respiratory syncytial
virus by a recombinant Newcastle disease virus vector. J Virol.
80:1130–1139. 2006.
|
|
9
|
Donahue JM, Mullen JT and Tanabe KK: Viral
oncolysis. Surg Oncol Clin N Am. 11:661–680. 2002.
|
|
10
|
Reichard KW, Lorence RM, Cascino CJ, et
al: Newcastle disease virus selectively kills human tumor cells. J
Surg Res. 52:448–453. 1992.
|
|
11
|
Elankumaran S, Rockemann D and Samal SK:
Newcastle disease virus exerts oncolysis by both intrinsic and
extrinsic caspase-dependent pathways of cell death. J Virol.
80:7522–7534. 2006.
|
|
12
|
Hrabák A, Csuka I, Bajor T and Csatáry LK:
The cytotoxic anti-tumor effect of MTH-68/H, a live attenuated
Newcastle disease virus is mediated by the induction of nitric
oxide synthesis in rat peritoneal macrophages in vitro. Cancer
Lett. 231:279–289. 2006.
|
|
13
|
Bian H, Fournier P, Peeters B and
Schirrmacher V: Tumor-targeted gene transfer in vivo via
recombinant Newcastle disease virus modified by a bispecific fusion
protein. Int J Oncol. 27:377–384. 2005.
|
|
14
|
Lorence RM, Rood PA and Kelley KW:
Newcastle disease virus as an antineoplastic agent: induction of
tumornecrosis factor-alpha and augmentation of its cytotoxicity. J
Natl Cancer Inst. 80:1305–1312. 1988.
|
|
15
|
Lorence RM, Reichard KW, Katubig BB, et
al: Complete regression of human neuroblastoma xenografts in
athymic mice after local Newcastle disease virus therapy. J Natl
Cancer Inst. 86:1228–1233. 1994.
|
|
16
|
Cassel WA and Murray DR: Treatment of
stage II malignant melanoma patients with a Newcastle disease virus
oncolysate. Nat Immun Cell Growth Regul. 7:351–352. 1988.
|
|
17
|
Wallack MK, Sivanandham M, Balch CM, et
al: Surgical adjuvant active specific immunotherapy for patients
with stage III melanoma: the final analysis of data from a phase
III, randomized, double-blind, multicenter vaccinia melanoma
oncolysate trial. J Am Coll Surg. 187:69–79. 1998.
|
|
18
|
Ashraf S, Singh PK, Yadav DK, et al: High
level expression of surface glycoprotein of rabies virus in tobacco
leaves and its immunoprotective activity in mice. J Biotechnol.
119:1–14. 2005.
|
|
19
|
Barth R, Diderrich G and Weinmann E: NIH
test, a problematic method for testing potency of inactivated
rabies vaccine. Vaccine. 6:369–377. 1988.
|
|
20
|
Ge J, Wang X, Tao L, et al: Newcastle
disease virus-vectored rabies vaccine is safe, highly immunogenic,
and provides long-lasting protection in dogs and cats. J Virol.
85:8241–8252. 2011.
|
|
21
|
Zamarin D and Palese P: Oncolytic
Newcastle disease virus for cancer therapy: old challenges and new
directions. Future Microbiol. 7:3347–3367. 2012.
|
|
22
|
Bazzoni F and Beutler B: The tumor
necrosis factor ligand and receptor families. N Engl J Med.
334:1717–1725. 1996.
|
|
23
|
Zou H, Li Y, Liu X and Wang X: An
APAF-1.cytochrome c multimeric complex is a functional apoptosome
that activates procaspase-9. J Biol Chem. 274:11549–11556.
1999.
|
|
24
|
Ravindra PV, Tiwari AK, Sharma B and
Chauhan RS: Newcastle disease virus as an oncolytic agent. Indian J
Med Res. 130:507–513. 2009.
|
|
25
|
Nelson NJ: Scientific interest in
Newcastle disease virus is reviving. J Nat Cancer Inst.
91:1708–1710. 1999.
|
|
26
|
Schirrmacher V, Haas C, Bonifer R, et al:
Human tumor cell modification by virus infection: an efficient and
safe way to pro duce cancer vaccine with pleiotropic immune
stimulatory properties when using Newcastle disease virus. Gene
Ther. 6:63–73. 1999.
|
|
27
|
Fiola C, Peeters B, Fournier P and Unsal
A: Tumor selective replication of Newcastle disease virus:
association with defects of tumor cells in antiviral defence. Int J
Cancer. 119:328–338. 2006.
|
|
28
|
Avki S, Turutoglu H, Simsek A and Unsal A:
Clinical and immunological effects of Newcastle disease virus
vaccine on bovine papillomatosis. Vet Immunol Immunopathol.
98:9–16. 2004.
|
|
29
|
Zeng J, Fournier P and Schirrmacher V:
Induction of interferon-alpha and tumor necrosis factor-related
apoptosis-inducing ligand in human blood mononuclear cells by
hemagglutinin-neuraminidase but not F protein of Newcastle disease
virus. Virology. 297:19–30. 2002.
|
